trending Market Intelligence /marketintelligence/en/news-insights/trending/VC5lxmlXfp_cB7kq2B-3zg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

AbbVie, AstraZeneca settle patent cases for cancer drugs Imbruvica, Calquence

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

AbbVie, AstraZeneca settle patent cases for cancer drugs Imbruvica, Calquence

Drugmakers AbbVie Inc. and AstraZeneca PLC have settled lawsuits between them that claimed their competitor's blood cancer treatment was in violation of their own patents.

AbbVie's Imbruvica — co-developed with Johnson & Johnson — is used to treat blood cancers like lymphoma and leukemia, and AstraZeneca's newer drug Calquence has been approved and is in trials for similar uses.

The companies filed the suits in the U.S. District Court in Delaware, where the agreement was approved Oct. 23. No terms of the settlement were released at that time.

AbbVie's Pharmacyclics unit sued AstraZeneca in 2017 after Calquence won U.S. Food and Drug Administration approval for mantle cell lymphoma. U.K.-based AstraZeneca fired back with a suit of its own.

Based on clinical trial results, the FDA has given Calquence a breakthrough therapy designation in chronic lymphocytic leukemia, giving AstraZeneca potentially faster access to the U.S. market that Imbruvica has already secured.